Novo Nordisk Parkinson's cell therapy sold to AI startup

Cellular Intelligence, an AI startup backed by Mark Zuckerberg, is acquiring STEM-PD, a Phase 2-ready stem cell therapy for Parkinson's disease, from Novo Nordisk. The deal includes plans to use artificial intelligence to accelerate development and manufacturing of the treatment. Novo Nordisk originally developed STEM-PD as a potential cell replacement therapy for Parkinson's. Financial terms of the acquisition were not disclosed. The move reflects a growing trend of AI companies acquiring traditional biotech assets to leverage computational approaches in drug development.